SWP
CRSP icon

Strategic Wealth Partners’s CRISPR Therapeutics CRSP Stock Holding History

Strategic Wealth Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.8K Sell
382
-225
-37% -$11.9K ﹤0.01% 738
2026
Q1 		$28.9K Hold
607
– – ﹤0.01% 625
2025
Q4 		$31.8K Sell
607
-243
-29% -$14.6K ﹤0.01% 602
2025
Q3 		$55.1K Buy
850
+37
+5% +$2.12K ﹤0.01% 533
2025
Q2 		$39.5K Buy
+813
New +$31.5K ﹤0.01% 540

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Strategic Wealth Partners's CRSP Position: Q2 2026 in Review

Strategic Wealth Partners reduced its CRISPR Therapeutics (CRSP) stake by 37% in Q2 2026, selling an estimated $11.9K and leaving 382 shares worth $20.8K. The position accounts for ﹤0.01% of the portfolio, ranked #738.

Strategic Wealth Partners first reported a position in CRSP in Q2 2025 and has held it in 5 quarters since. The position peaked at $55.1K in Q3 2025. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Strategic Wealth Partners held 382 shares of CRISPR Therapeutics worth $20.8K as of Q2 2026.
  • Strategic Wealth Partners sold 225 CRISPR Therapeutics shares in Q2 2026, an estimated $11.9K.
  • CRISPR Therapeutics made up ﹤0.01% of Strategic Wealth Partners's portfolio in Q2 2026, its #738 holding.
  • Strategic Wealth Partners first reported a position in CRISPR Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Strategic Wealth Partners's CRISPR Therapeutics position peaked at $55.1K in Q3 2025.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Strategic Wealth Partners's 13F filing for Q2 2026, filed 12 Aug 2026.